Asia Pacific Spinal Muscular Atrophy Treatment Market Size, Share & Industry Trends Analysis Report By Type (Type 1, Type 2, Type 3 and Type 4), By Route of Administration, By Treatment Type (Drug and Gene Therapy), By Drug Type, By Country and Growth Forecast, 2022 - 2028

The Asia Pacific Spinal Muscular Atrophy Treatment Market would witness market growth of 19.4% CAGR during the forecast period (2022-2028).

Survival motor neuron gene 2 (SMN2), often known as the SMA backup gene, is a second gene that is present in all people with SMA in at least one and frequently numerous copies. Although SMN2 also creates SMN protein, the body can only utilize a limited portion of this protein. Numerous therapies that increase the usability of SMN protein target the SMN2 gene. Other SMN-enhancing methods directly replace or correct the mutated SMN1 gene.

Considering motor neurons are the cells most severely impacted by SMA, neuroprotective measures directed at this group of neurons may be successful, especially when combined with SMN-restoring therapy. One of the main symptoms of SMA type 2/3 is repeated nerve conduction and increased fatigability investigations reveal a decline, indicating that neuromuscular junction (NMJ) dysfunction may be significantly contributing to fatigability.

Therefore, pyridostigmine, an acetylcholinesterase inhibitor commonly recommended for myasthenia gravis, is presently being studied in phase II clinical trials to determine its impact on the efficiency of cholinergic transmission. According to early observations, pyridostigmine decreases patient fatigability and therefore, is considered a potential supplementary therapy.

Several studies were conducted in this region to figure out the psychosocial impacts of SMA on patients, families, and caretakers. More than half of the participants reported experiencing stress, and the majority of the caregivers reported experiencing anxiety. This is consistent with earlier studies that reported the great emotional costs associated with living with SMA. This may be because getting psychological counseling is culturally stigmatized in Asia, where people are taught to keep their emotions to themselves.

The China market dominated the Asia Pacific Spinal Muscular Atrophy Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $523.6 million by 2028. The Japan market is estimated to grow a CAGR of 18.6% during (2022 - 2028). Additionally, The India market would experience a CAGR of 20.1% during (2022 - 2028).

Based on Type, the market is segmented into Type 1, Type 2, Type 3 and Type 4. Based on Route of Administration, the market is segmented into Injection and Oral. Based on Treatment Type, the market is segmented into Drug and Gene Therapy. Based on Drug Type, the market is segmented into Spinraza, Zolgensma (AVXS-101), Evrysdi and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Australia, Malaysia, and Rest of Asia Pacific.

Free Valuable Insights: The Worldwide Spinal Muscular Atrophy Treatment Market is Projected to reach USD 11.4 Billion by 2028, at a CAGR of 17.8%

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Biogen, Inc., Novartis AG, Ionis Pharmaceuticals, Inc., PTC Therapeutics, Inc., NMD Pharma A/S, Scholar Rock, Inc. (Scholar Rock Holding Corporation), Cytokinetics, Inc., Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.), Astellas Pharma, Inc., and F. Hoffmann-La Roche Ltd. (Genentech, Inc.)

Scope of the Study

Market Segments Covered in the Report:

By Type

• Type 1
• Type 2
• Type 3
• Type 4

By Route of Administration

• Injection
• Oral

By Treatment Type

• Drug
  • Spinraza
  • Zolgensma (AVXS-101)
  • Evrysdi
  • Others
• Gene Therapy

By Country

• China
• Japan
• India
• South Korea
• Australia
• Malaysia
• Rest of Asia Pacific

Key Market Players

List of Companies Profiled in the Report:

• Biogen, Inc.
• Novartis AG
• Ionis Pharmaceuticals, Inc.
• PTC Therapeutics, Inc.
• NMD Pharma A/S
• Scholar Rock, Inc. (Scholar Rock Holding Corporation)
• Cytokinetics, Inc.
• Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.)
• Astellas Pharma, Inc.
• F.Hoffmann-La Roche Ltd. (Genentech, Inc.)

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Spinal Muscular Atrophy Market, by Type
1.4.2 Asia Pacific Spinal Muscular Atrophy Market, by Route of Administration
1.4.3 Asia Pacific Spinal Muscular Atrophy Market, by Treatment Type
1.4.4 Asia Pacific Spinal Muscular Atrophy Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Strategies Deployed in Spinal Muscular Atrophy Market

Chapter 4. Asia Pacific Spinal Muscular Atrophy Treatment Market by Type
4.1 Asia Pacific Type 1 Market by Country
4.2 Asia Pacific Type 2 Market by Country
4.3 Asia Pacific Type 3 Market by Country
4.4 Asia Pacific Type 4 Market by Country

Chapter 5. Asia Pacific Spinal Muscular Atrophy Treatment Market by Route of Administration
5.1 Asia Pacific Injection Market by Country
5.2 Asia Pacific Oral Market by Country

Chapter 6. Asia Pacific Spinal Muscular Atrophy Treatment Market by Treatment Type
6.1 Asia Pacific Drug Market by Country
6.2 Asia Pacific Spinal Muscular Atrophy Treatment Market by Drug Type
6.2.1 Asia Pacific Spinraza Market by Country
6.2.2 Asia Pacific Zolgensma (AVXS-101) Market by Country
6.2.3 Asia Pacific Evrysdi Market by Country
6.2.4 Asia Pacific Others Market by Country
6.3 Asia Pacific Gene Therapy Market by Country

Chapter 7. Asia Pacific Spinal Muscular Atrophy Treatment Market by Country
7.1 China Spinal Muscular Atrophy Treatment Market
7.1.1 China Spinal Muscular Atrophy Treatment Market by Type
7.1.2 China Spinal Muscular Atrophy Treatment Market by Route of Administration
7.1.3 China Spinal Muscular Atrophy Treatment Market by Treatment Type
7.1.3.1 China Spinal Muscular Atrophy Treatment Market by Drug Type
7.2 Japan Spinal Muscular Atrophy Treatment Market
7.2.1 Japan Spinal Muscular Atrophy Treatment Market by Type
7.2.2 Japan Spinal Muscular Atrophy Treatment Market by Route of Administration
7.2.3 Japan Spinal Muscular Atrophy Treatment Market by Treatment Type
7.2.3.1 Japan Spinal Muscular Atrophy Treatment Market by Drug Type
7.3 India Spinal Muscular Atrophy Treatment Market
7.3.1 India Spinal Muscular Atrophy Treatment Market by Type
7.3.2 India Spinal Muscular Atrophy Treatment Market by Route of Administration
7.3.3 India Spinal Muscular Atrophy Treatment Market by Treatment Type
7.3.3.1 India Spinal Muscular Atrophy Treatment Market by Drug Type
7.4 South Korea Spinal Muscular Atrophy Treatment Market
7.4.1 South Korea Spinal Muscular Atrophy Treatment Market by Type
7.4.2 South Korea Spinal Muscular Atrophy Treatment Market by Route of Administration
7.4.3 South Korea Spinal Muscular Atrophy Treatment Market by Treatment Type
7.4.3.1 South Korea Spinal Muscular Atrophy Treatment Market by Drug Type
7.5 Australia Spinal Muscular Atrophy Treatment Market
7.5.1 Australia Spinal Muscular Atrophy Treatment Market by Type
7.5.2 Australia Spinal Muscular Atrophy Treatment Market by Route of Administration
7.5.3 Australia Spinal Muscular Atrophy Treatment Market by Treatment Type
7.5.3.1 Australia Spinal Muscular Atrophy Treatment Market by Drug Type
7.6 Malaysia Spinal Muscular Atrophy Treatment Market
7.6.1 Malaysia Spinal Muscular Atrophy Treatment Market by Type
7.6.2 Malaysia Spinal Muscular Atrophy Treatment Market by Route of Administration
7.6.3 Malaysia Spinal Muscular Atrophy Treatment Market by Treatment Type
7.6.3.1 Malaysia Spinal Muscular Atrophy Treatment Market by Drug Type
7.7 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market
7.7.1 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Type
7.7.2 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Route of Administration
7.7.3 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Treatment Type
7.7.3.1 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Drug Type

Chapter 8. Company Profiles
8.1 PTC Therapeutics, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Acquisition and Mergers:
8.1.5.3 Approvals and Trials:
8.2 F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Approvals and Trials:
8.2.5.2 Acquisition and Mergers:
8.3 Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.)
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional & Segmental Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.4 Novartis AG
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Approvals and Trials:
8.4.5.2 Acquisition and Mergers:
8.5 Ionis Pharmaceuticals, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Research & Development Expenses
8.5.4 Recent strategies and developments:
8.5.4.1 Acquisition and Mergers:
8.6 Scholar Rock, Inc. (Scholar Rock Holding Corporation)
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Research & Development Expenses
8.7 Cytokinetics, Incorporated
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Research & Development Expenses
8.8 Astellas Pharma, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expense
8.9 Biogen, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expense
8.10. NMD Pharma A/S
8.10.1 Company Overview
8.10.2 Recent strategies and developments:
8.10.2.1 Geographical Expansions:

TABLE 1 Asia Pacific Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
TABLE 2 Asia Pacific Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
TABLE 3 Asia Pacific Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
TABLE 4 Asia Pacific Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
TABLE 5 Asia Pacific Type 1 Market by Country, 2018 - 2021, USD Million
TABLE 6 Asia Pacific Type 1 Market by Country, 2022 - 2028, USD Million
TABLE 7 Asia Pacific Type 2 Market by Country, 2018 - 2021, USD Million
TABLE 8 Asia Pacific Type 2 Market by Country, 2022 - 2028, USD Million
TABLE 9 Asia Pacific Type 3 Market by Country, 2018 - 2021, USD Million
TABLE 10 Asia Pacific Type 3 Market by Country, 2022 - 2028, USD Million
TABLE 11 Asia Pacific Type 4 Market by Country, 2018 - 2021, USD Million
TABLE 12 Asia Pacific Type 4 Market by Country, 2022 - 2028, USD Million
TABLE 13 Asia Pacific Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 14 Asia Pacific Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 15 Asia Pacific Injection Market by Country, 2018 - 2021, USD Million
TABLE 16 Asia Pacific Injection Market by Country, 2022 - 2028, USD Million
TABLE 17 Asia Pacific Oral Market by Country, 2018 - 2021, USD Million
TABLE 18 Asia Pacific Oral Market by Country, 2022 - 2028, USD Million
TABLE 19 Asia Pacific Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
TABLE 20 Asia Pacific Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
TABLE 21 Asia Pacific Drug Market by Country, 2018 - 2021, USD Million
TABLE 22 Asia Pacific Drug Market by Country, 2022 - 2028, USD Million
TABLE 23 Asia Pacific Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
TABLE 24 Asia Pacific Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
TABLE 25 Asia Pacific Spinraza Market by Country, 2018 - 2021, USD Million
TABLE 26 Asia Pacific Spinraza Market by Country, 2022 - 2028, USD Million
TABLE 27 Asia Pacific Zolgensma (AVXS-101) Market by Country, 2018 - 2021, USD Million
TABLE 28 Asia Pacific Zolgensma (AVXS-101) Market by Country, 2022 - 2028, USD Million
TABLE 29 Asia Pacific Evrysdi Market by Country, 2018 - 2021, USD Million
TABLE 30 Asia Pacific Evrysdi Market by Country, 2022 - 2028, USD Million
TABLE 31 Asia Pacific Others Market by Country, 2018 - 2021, USD Million
TABLE 32 Asia Pacific Others Market by Country, 2022 - 2028, USD Million
TABLE 33 Asia Pacific Gene Therapy Market by Country, 2018 - 2021, USD Million
TABLE 34 Asia Pacific Gene Therapy Market by Country, 2022 - 2028, USD Million
TABLE 35 Asia Pacific Spinal Muscular Atrophy Treatment Market by Country, 2018 - 2021, USD Million
TABLE 36 Asia Pacific Spinal Muscular Atrophy Treatment Market by Country, 2022 - 2028, USD Million
TABLE 37 China Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
TABLE 38 China Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
TABLE 39 China Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
TABLE 40 China Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
TABLE 41 China Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 42 China Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 43 China Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
TABLE 44 China Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
TABLE 45 China Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
TABLE 46 China Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
TABLE 47 Japan Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
TABLE 48 Japan Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
TABLE 49 Japan Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
TABLE 50 Japan Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
TABLE 51 Japan Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 52 Japan Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 53 Japan Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
TABLE 54 Japan Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
TABLE 55 Japan Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
TABLE 56 Japan Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
TABLE 57 India Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
TABLE 58 India Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
TABLE 59 India Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
TABLE 60 India Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
TABLE 61 India Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 62 India Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 63 India Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
TABLE 64 India Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
TABLE 65 India Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
TABLE 66 India Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
TABLE 67 South Korea Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
TABLE 68 South Korea Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
TABLE 69 South Korea Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
TABLE 70 South Korea Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
TABLE 71 South Korea Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 72 South Korea Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 73 South Korea Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
TABLE 74 South Korea Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
TABLE 75 South Korea Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
TABLE 76 South Korea Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
TABLE 77 Australia Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
TABLE 78 Australia Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
TABLE 79 Australia Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
TABLE 80 Australia Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
TABLE 81 Australia Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 82 Australia Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 83 Australia Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
TABLE 84 Australia Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
TABLE 85 Australia Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
TABLE 86 Australia Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
TABLE 87 Malaysia Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
TABLE 88 Malaysia Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
TABLE 89 Malaysia Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
TABLE 90 Malaysia Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
TABLE 91 Malaysia Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 92 Malaysia Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 93 Malaysia Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
TABLE 94 Malaysia Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
TABLE 95 Malaysia Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
TABLE 96 Malaysia Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
TABLE 97 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market, 2018 - 2021, USD Million
TABLE 98 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market, 2022 - 2028, USD Million
TABLE 99 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Type, 2018 - 2021, USD Million
TABLE 100 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Type, 2022 - 2028, USD Million
TABLE 101 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Route of Administration, 2018 - 2021, USD Million
TABLE 102 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Route of Administration, 2022 - 2028, USD Million
TABLE 103 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Treatment Type, 2018 - 2021, USD Million
TABLE 104 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Treatment Type, 2022 - 2028, USD Million
TABLE 105 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Drug Type, 2018 - 2021, USD Million
TABLE 106 Rest of Asia Pacific Spinal Muscular Atrophy Treatment Market by Drug Type, 2022 - 2028, USD Million
TABLE 107 Key Information – PTC Therapeutics, Inc.
TABLE 108 key information – F. Hoffmann-La Roche Ltd.
TABLE 109 Key Information – Biohaven Pharmaceutical Holding Company Ltd.
TABLE 110 Key Information – Novartis AG
TABLE 111 Key information – Ionis Pharmaceuticals, Inc.
TABLE 112 Key Information – Scholar Rock, Inc.
TABLE 113 Key Information – CYTOKINETICS, INCORPORATED
TABLE 114 key information – Astellas Pharma, Inc.
TABLE 115 Key Information – Biogen, Inc.
TABLE 116 Key Information – nmd pharma a/s

List of Figures
FIG 1 Methodology for the research
FIG 2 Recent strategies and developments: PTC Therapeutics, Inc.